{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:32Z","timestamp":1760130212217},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.molmed.2012.01.006","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T10:53:28Z","timestamp":1330426408000},"page":"201-205","source":"Crossref","is-referenced-by-count":6,"title":["On rat poison and human medicines: personalizing warfarin therapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Felix W.","family":"Frueh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2012.01.006_bib0005","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0010","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","article-title":"National surveillance of emergency department visits for outpatient adverse drug events","volume":"296","author":"Budnitz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.molmed.2012.01.006_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pds.1953","article-title":"Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults","volume":"19","author":"Kim","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.molmed.2012.01.006_bib0020","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1016\/S0021-9258(17)34443-5","article-title":"Regioselective and stereoselective hydroxylation of R and S warfarin by different forms of purified cytochrome P-450 from rabbit liver","volume":"253","author":"Fasco","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2012.01.006_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.molmed.2012.01.006_bib0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00008571-199710000-00004","article-title":"Genetic association between sensitivity to warfarin and expression of CYP2C9*3","volume":"7","author":"Steward","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.molmed.2012.01.006_bib0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2012.01.006_bib0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2012.01.006_bib0045","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.tpj.6500046","article-title":"Pharmacogenomic-guided drug development: regulatory perspective","volume":"2","author":"Lesko","year":"2002","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.molmed.2012.01.006_bib0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/0091270003252244","article-title":"Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop","volume":"43","author":"Lesko","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.molmed.2012.01.006_bib0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd1499","article-title":"Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective","volume":"3","author":"Lesko","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2012.01.006_bib0065","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","article-title":"CYP4F2 genetic variant alters required warfarin dose","volume":"111","author":"Caldwell","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2012.01.006_bib0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1592\/phco.29.3.245","article-title":"Warfarin and pharmacogenomic testing: what would Pascal do?","volume":"29","author":"Teagarden","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.molmed.2012.01.006_bib0075","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2011.08.009","article-title":"Considerations for safety pharmacogenetics in clinical practice","volume":"16","author":"Frueh","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2012.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/pgs.09.62","article-title":"Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine","volume":"10","author":"Frueh","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.molmed.2012.01.006_bib0085","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.molmed.2012.01.006_bib0090","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0095","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options \u2013 why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0100","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jacc.2010.03.009","article-title":"Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)","volume":"55","author":"Epstein","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.molmed.2012.01.006_bib0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/GIM.0b013e31820ad77d","article-title":"A randomized controlled trial of genotype-based Coumadin initiation","volume":"13","author":"Burmester","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0110","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2012.01.006_bib0115","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2012.01.006_bib0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11239-010-0459-3","article-title":"Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic","volume":"30","author":"Shaw","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.molmed.2012.01.006_bib0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2353\/jmoldx.2010.090110","article-title":"Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing","volume":"12","author":"Roper","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.molmed.2012.01.006_bib0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/hj.1999.v137.91403","article-title":"Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation","volume":"137","author":"Flaker","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.molmed.2012.01.006_bib0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/014107680009300308","article-title":"Underutilization of antithrombotic therapy in atrial fibrillation","volume":"93","author":"Adhiyaman","year":"2000","journal-title":"J. R. Soc. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2011.306","article-title":"Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey","author":"Stanek","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2012.01.006_bib0180","article-title":"On pharmacogenomics in pharmacy benefit management","author":"Teagarden","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.molmed.2012.01.006_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0160","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","article-title":"Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation","volume":"123","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2012.01.006_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.molmed.2012.01.006_bib0170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-153-9-201011020-00010","article-title":"Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership","volume":"153","author":"Stang","year":"2010","journal-title":"Ann. Intern. Med."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491412000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491412000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T17:45:18Z","timestamp":1640972718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491412000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1471491412000093"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2012.01.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}